We investigated the current perception threshold (CPT) of epileptic patients treated with valproate. The CPTs at frequencies of 5 Hz, 250 Hz and 2000 Hz in the control group of patients were 198.9 ± 15.8, 62.0 ± 18.9 and 35.3 ± 15.8, respectively. The CPTs at 5 Hz, 250 Hz and 2000 Hz in the epileptic group of patients were 350.6 ± 61.3, 338.6 ± 64.3 and 193.2 ± 21.1, respectively. The CPTs at 5 Hz, 250 Hz and 2000 Hz in the epileptic group were significantly higher than those of the control group. We measured the CPTs for 6 months after the administration of valproate in three patients with traumatic epilepsy. Their CPTs were higher than that of the epileptic group. The CPTs at 5 Hz, 250 Hz and 2000 Hz reached a maximum 4 weeks after the administration of valproate for two of these patients and in 6 weeks for the other patient. When the administration of valproate to a patient was stopped, CPTs decreased.
INTRODUCTION
Pain perception thresholds of patients with epilepsy are suggested to be higher than those of healthy subjects 1 . These patients do not complain of pain, in spite of having severe traumatic lesions 1 . The lack of pain in patients with epilepsy is considered to result from either the epileptic condition or its treatment. Antiepileptic drugs are known to have strong analgesic effects 2 and are used for the therapy of neuropathic pain and migraine 3 . Valproate is often preferred to carbamazepine, phenytoin, benzodiazepines and phenobarbitones because valproate may be better tolerated 4, 5 . Valproate easily crosses the blood-brain barrier and increases γ -aminobutyric acid (GABA) concentration in various areas of the CNS 6 . GABA is the most important inhibitory neurotransmitter in the brain and plays a role in analgesia 7 as well as epilepsy. On the other hand, an increase in β-endorphin levels has been reported to occur in the CSF of patients with epilepsy 8 . However, their β-endorphin levels are normal during seizure-free periods 9 . Thus, it is possible that the lack of pain during seizure-free periods is caused by anticonvulsants.
Pain has been subjectively assessed by means of verbal or visual intensity scales. However, it has recently become possible to objectively evaluate human pain threshold levels using the neurometer. The neurometer is a non-invasive device and can measure the sensitivity to electric current or current perception threshold (CPT) 10 . It can test different types of nerve fibres by using different frequencies of electric stimulation; 2000 Hz for Aβ, 250 Hz for Aσ and 5 Hz for C fibres 11 . There is no previous data on CPT testing in epileptic patients treated with valproate. Therefore, in the present study, we set out to assess peripheral sensory nerve function in epileptic patients treated with valproate.
PATIENTS AND METHODS
The study was approved by our institutional medical ethics committee. Informed consent was obtained from each patient. We studied 14 epileptic patients, ranging in age from 22 to 40 years and 25 patients as the control, ranging in age from 16 to 45 years. The 25 control patients were randomly selected out of healthy patients and were not treated with any medication. The diagnosis of epilepsy was made by neurologists. The epileptic patients had been given a daily dose of 300-900 mg of valproate in three divided doses. The dose of medication had been stable for at least a year before the study. These epileptic patients were treated with valproate for at least 3 years before the study and were not treated with any other antiepileptic drugs. All patients had been seizure-free for more than 120 hours when undergoing these tests. None of these patients were suffering from peripheral neuropathic disorder or central pain.
Assessment for peripheral sensory nerve function was performed in a quiet room by Neurometer CPT (Toyomedic, Tokyo, Japan) the day before the operation. The test was performed by physiotherapists who did not have any knowledge or information about the study. The equipment is a neuroselective transcutaneous electric stimulator which generates a sinusoidal waveform from a constant current stimulator, adjustable from 0 to 10 milliamperes ( Two small gold-plated surface electrodes were applied: one on the lateral and the other on the medical aspect of the index finger. The current was slowly increased until the patient reported sensation. The stimulation was turned off, then the intensity was lowered 100 µA and the stimulation was turned back on. This procedure was repeated until a range of 100 µA was established, at which level the patient reported feeling the high intensity and could not perceive the lower intensity. Using a standardized double-blind methodology, the patient was then presented with a minimum of six cycles of randomly selected real and false stimulations, above and below their perception threshold level, until the exact CPT value was determined within a ±20 µA range. CPT scores define 0.01 mA as '1' and 10 mA as '1000'.
Plasma valproate levels were measured using a fluorescence polarization immunoassay method. The plasma levels of valproate were expressed as the average of three measurements.
The Wilcoxon and Mann-Whitney U -tests were used for data analysis and a P < 0.05 was considered significant. All data were presented as mean ± SEM.
RESULTS
There were no significant differences in age, weight or height between the control group and the epileptic group. Mean plasma concentration of valproate was 36.2 µg ml −1 . We could not find a correlation between CPTs and plasma valproate levels (CPT at 5 Hz vs. plasma valproate levels, r = 0.51, P = 0.06; CPT at 250 Hz vs. plasma valproate levels, r = 0.43, P = 0.12; CPT at 2000 Hz vs. plasma valproate levels, r = 0.44, P = 0.11) or between CPTs and duration of its administration (CPT at 5 Hz vs. duration, r = 0.34, P = 0.24; CPT at 250 Hz vs. duration, r = 0.17, P = 0.56; CPT at 2000 Hz vs. duration, r = 0.01, P = 0.98).
We measured CPT prior to and for 6 months after the administration of valproate in three patients with traumatic epilepsy. Their CPTs were higher than that of the epileptic group. The CPTs at 5 Hz, 250 Hz and 2000 Hz reached a maximum 4 weeks after the administration of valproate for two of these patients and in 6 weeks for the other patient.
DISCUSSION
The present study demonstrated that epileptic patients treated with valproate had increased CPTs at frequencies of 5 Hz, 250 Hz and 2000 Hz. Valproate is one of the major antiepileptic drugs and is also used for the therapy of neuropathic pain 3 . Valproate increases GABA synthesis, reduces neuronal excitation induced by NMDA-type glutamate receptors and alters serotonergic function 12 . Inhibition of GABA and NMDA receptors attenuates or inhibits nociceptive response 13, 14 . Thus, the actions of valproate on GABA receptors, NMDA receptors and serotonin appear to contribute to increased CPTs. In this study, an increase in CPTs at 5 Hz and 250 Hz was more remarkable than that of CPTs at 2000 Hz. Stimulation of C fibres induced by pinch and heat is inhibited by GABA agonists 15 , but the relationship between Aβ, Aσ and GABA receptors is unknown. Local anaesthetic blockade of peripheral nerves also selectively elevates the 5 Hz and 250 Hz thresholds without affecting the 2000 Hz threshold and the same finding is found by intravenous lidocaine administration 16 . The mechanism by which valproate and lidocaine do not affect the 2000 Hz threshold remains unclarified, but it is interesting that both drugs show the same phenomenon. Probably, valproate and lidocaine can produce a selective block of Aσ and C fibres in spinal cord or supraspinal lesions. Thus, valproate may have more influence on small nerve fibres. An increase in β-endorphin levels has been reported to occur in the CSF of patients after a generalized epileptic seizure 8 , but β-endorphin levels are normal during seizure-free periods 9 . Guieu et al. 1 found that the nociceptive threshold of patients with epilepsy did not differ from that of healthy, control patients. In this study, we measured CPTs prior to and for 6 months after the administration of valproate in three patients with traumatic epilepsy. CPTs of these patients markedly increased. This result supports the theory that the absence of pain in patients with epilepsy is mainly caused by valproate. In addition, their CPT values were higher than the CPTs of patients with chronic administration of valproate. The decrease in CPTs of patients with chronic administration of valproate is probably caused by tolerance to the pharmacological effects after long-term treatment with this drug.
Neurometer applies a sinusoidal alternation constant current output to the skin at three frequencies including 5 Hz, 250 Hz and 2000 Hz. It is used as a quantita-tive test of sensory function for the diagnosis and monitoring of clinical condition. Most neurometric tests evaluate a single and specific aspect of nerve function. As the nerve conduction test (NCT) is determined by the large diameter fibres, this test does not always correlate with clinically painful symptoms 17 . Vibratory and thermal tests are also each limited to the excitation of a single specialized type of sensory nerve ending and thus cannot provide a broad-range evaluation of nerve integrity 18 . In addition, as CPTs selectively excite three different subpopulations of axons in a peripheral nerve with constant current feedback control circuits, detection of nerve impairment will increase.
The present study showed that an increased sensory threshold was not related to plasma valproate concentrations. Poor correlation between anticonvulsant action and plasma valproate concentrations is suggested 19 . For pain relief, the best prophylactic effect of valproate in migraine was at a plasma concentration of approximately 120 µg ml −1 (700 µmoll −1 ) 20 . The value is approximately three times higher than that of this study. Plasma concentration of this drug appears not to correlate with clinical effects.
In conclusion, epileptic patients with valproate had increased current perception thresholds in all of Aβ, Aσ and C fibres. The increased sensory threshold appears to be caused by treatment with valproate rather than by the epileptic condition, because current perception threshold in three patients with traumatic epilepsy markedly increased after the administration of valproate.
